A5038090842- Thyroid Cancer Diagnosis and Treatment
- Thyroid Disorders and Treatments
- Thyroid and Parathyroid Surgery
- Growth Hormone and Insulin-like Growth Factors
- Pituitary Gland Disorders and Treatments
- Ion channel regulation and function
- Medical Imaging Techniques and Applications
- Hormonal Regulation and Hypertension
- BRCA gene mutations in cancer
- Radiation Dose and Imaging
- Healthcare Systems and Technology
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Anomalies
- Genetic factors in colorectal cancer
- Radiopharmaceutical Chemistry and Applications
- Neuroscience of respiration and sleep
- Primary Care and Health Outcomes
- Vitamin D Research Studies
- Lipoproteins and Cardiovascular Health
- Advanced Radiotherapy Techniques
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer-related Molecular Pathways
- Vitamin K Research Studies
- Electrolyte and hormonal disorders
- Neuroendocrine Tumor Research Advances
Johns Hopkins Medicine
2015-2024
Johns Hopkins University
2015-2024
The Ohio State University
2004-2017
Amsterdam UMC Location University of Amsterdam
2014
Centers for Disease Control and Prevention
2012
Division of Parasitic Diseases and Malaria
2012
North Central Cancer Treatment Group
2012
Southern Arizona VA Health Care System
2009
Uppsala University
2009
Welch Foundation
2004
Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification this cancer. Objective: The objective study was investigate prognostic value patients with PTC. Design, Setting, and Subjects: In a multicenter 219 PTC patients, data on their clinicopathological characteristics clinical courses between 1990 2004 were retrospectively collected, tumor status determined. Associations initial subsequent recurrence analyzed. Main Outcome Measure:...
The BRAF gene has been found to be activated by mutation in human cancers, predominantly malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, 17 prostate for the T1796A polymerase chain reaction (PCR)-restriction enzyme analysis of exon 15. In 24 (69%) 35 papillary thyroid carcinomas examined, we a missense thymine (T)-->adenine (A) transversion at nucleotide 1796 (T1796A). was detected four lung cancers six neck but...
BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role PTC-related patient mortality has not been established.To investigate the relationship between mutation and mortality.Retrospective study of 1849 patients (1411 women 438 men) with median age 46 years (interquartile range, 34-58 years) an overall follow-up time 33 months 13-67 months) after initial treatment at 13 centers 7 countries 1978 2011.Patient deaths specifically caused by PTC.Overall, was 5.3%...
ContextPrevious studies have suggested that subclinical abnormalities in thyroid-stimulating hormone levels are associated with detrimental effects on the cardiovascular system.ObjectiveTo determine relationship between baseline thyroid status and incident atrial fibrillation, disease, mortality older men women not taking medication.Design, Setting, ParticipantsA total of 3233 US community-dwelling individuals aged 65 years or serum were enrolled 1989-1990 Cardiovascular Health Study, a...
This analysis was performed to determine the effect of initial therapy on outcomes thyroid cancer patients. The study setting a prospectively followed multi-institutional registry. Patients were stratified as low risk (stages I and II) or high III IV). Treatments employed included near-total thyroidectomy, administration radioactive iodine, hormone suppression therapy. Outcome measures overall survival, disease-specific disease-free survival. Near-total aggressive each independently...
<h3>Objective</h3> To define the optimal approach to identify patients with thyroid dysfunction. <h3>Participants</h3> The 8-member Standards of Care Committee American Thyroid Association prepared a draft, which was reviewed by association's 780 members, 50 whom responded suggested revisions. <h3>Evidence</h3> Relevant published studies were identified through MEDLINE and association membership's personal resources. <h3>Consensus Process</h3> Consensus reached at group meetings. first draft...
Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after hormone withdrawal. The objectives this study were compare effect administered recombinant with withdrawal on results radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels. Two hundred twenty-nine adult patients differentiated cancer requiring WBS studied. Radioiodine Tg measurements performed...
To detect recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of hormone therapy may be required to raise serum thyrotropin concentrations stimulate tissue so that radioiodine (iodine-131) scanning can performed. However, causes hypothyroidism. Administration recombinant human stimulates without requiring the discontinuation therapy.
<h3>Objective.</h3> —To develop a set of minimum clinical guidelines for use by primary care physicians in the evaluation and management patients with hyperthyroidism hypothyroidism. <h3>Participants.</h3> —Guidelines were developed nine-member ad hoc Standards Care Committee American Thyroid Association (the authors this article). The participants selected committee chair president on basis their experience. members represented different geographic areas within United States, order to take...
BACKGROUND A novel prognostic staging classification encompassing all forms of thyroid carcinoma was created for the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) Registry, with goal prospective validation and comparison other available classifications. METHODS Patient information recorded prospectively from 14 institutions. Clinicopathologic based on patient age at diagnosis, tumor histology, size, intrathyroidal multifocality, extraglandular invasion, metastases,...
<h3>Importance</h3> Use of next-generation sequencing RNA and machine learning algorithms can classify the risk malignancy in cytologically indeterminate thyroid nodules to limit unnecessary diagnostic surgery. <h3>Objective</h3> To measure performance a genomic classifier for nodules. <h3>Design, Setting, Participants</h3> A blinded validation study was conducted on set collected by fine-needle aspiration biopsy between June 2009 December 2010 from 49 academic community centers United...
Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels serum low-density lipoprotein (LDL) cholesterol has other potentially favorable actions on metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.We performed a randomized, placebo-controlled, double-blind, multicenter trial to assess safety efficacy compound...
BRAF V600E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC). This genetic duet was indicated to be involved the aggressiveness of PTC, but its prognostic value PTC-related mortality remains specifically established.To establish power this PTC-specific mortality.This genetic-clinical correlation study examined (chr5:1,295,228C>T chr5:1,295,250C>T) 1051 patients (764 women 287 men) with a median (interquartile range [IQR]) age 46 (36-57) years, (IQR) follow-up time 89...
Many changes in health care delivery, legislation, and the physician workforce that affect supply demand for endocrinology services have occurred since first published study of adult endocrinologists 2003. The objective was to assess current data provide analysis pediatric project through 2025. A model developed from an proprietary publicly available databases, consultation with a technical expert panel, results online survey board-certified endocrinologists. Endocrine Society commissioned...
The ideal therapy for differentiated thyroid cancer is uncertain. Although hormone treatment pivotal, the degree of thyrotropin (TSH) suppression that required to prevent recurrences has not been studied in detail. We have examined relation TSH baseline disease characteristics and likelihood progression a cohort patients who followed multicenter registry was established 1986. present study describes 617 with papillary 66 follicular annually median 4.5 years (range 1-8.6 years). Cancer...